You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Efficacy

Flixotide offers improved outcomes compared to LTRA

Starting low-dose ICS early in (≤6 months of symptoms) mild or moderate asthma leads to greater improvement in lung function than starting treatment later.1,2

Go to Close Top

Reference:

  1. Selroos O, et al. Chest 1995; 108 (5): 1228-1234.
  2. Global Strategy for Asthma Management and Prevention 2018, © Global Initiative for Asthma (GINA) all rights reserved. Available from http://www.ginasthma.org
  3. Ostrom NK, et al. J Paediatr 2005;147(2):213–220.

Flixotide is a trademark of GlaxoSmithKline group of companies.
To report an Adverse Event, please contact the toll free line 0800 CALL GSK (0800 2255 475) or send an
email.